Nightingale secures global scalability of its at-home solution by partnering with at-home blood collection device manufacturer Weavr with new commercial terms and minority investment
Company ReleaseInside Information29 June 2021 at 9:40 a.m. (Finnish Time)Nightingale Health Plc (“Nightingale”), and Weavr Health Corp. (“Weavr”, formerly Boston MicroFluidics, Inc.) have established a strategic partnership by expanding the existing distribution agreement between the parties with new commercial terms. The new commercial terms are effective as of today. Nightingale today also closed a minority investment to Weavr. Weavr is the manufacturer of the Velvet™ device, which Nightingale uses in its at-home pilot launched in the second quarter of 2021. The agreed strategic